Candel Therapeutics
CADL
45 hedge funds and large institutions have $37M invested in Candel Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.
519% more capital invested
Capital invested by funds: $5.97M → $37M (+$31M)
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
125% more funds holding
Funds holding: 20 → 45 (+25)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6.96% more ownership
Funds ownership: 13.07% → 20.03% (+7%)
10% less call options, than puts
Call options by funds: $548K | Put options by funds: $612K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.82M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.34M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.87M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.08M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
-$3.05M |
| 2 |
Renaissance Technologies
New York
|
-$272K |
| 3 |
Mariner
Overland Park,
Kansas
|
-$52.9K |
| 4 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$47.1K |
| 5 |
TIA
Traphagen Investment Advisors
Oradell,
New Jersey
|
-$27.2K |
CADL Hedge Fund Activity: Q2 2024 in Review
45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q2 2024, worth a combined $37M — up 519% from $5.97M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CADL positions and 6 closed out — a net gain of 25 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $5.82M. The largest seller was Sands Capital Ventures, cutting an estimated $3.05M.
- 45 institutional investors held Candel Therapeutics (CADL) as of Q2 2024, up from 20 in Q1 2024.
- Funds reported $37M of Candel Therapeutics stock for Q2 2024, up 519% quarter-over-quarter.
- 31 funds opened new Candel Therapeutics positions in Q2 2024 and 6 closed out, a net change of +25 holders.
- The largest Candel Therapeutics buyer in Q2 2024 was BlackRock, an estimated $5.82M added.
- The largest Candel Therapeutics seller in Q2 2024 was Sands Capital Ventures, an estimated $3.05M sold.
Based on aggregated 13F filings for Q2 2024.